Copan Diagnostics has received the US Food and Drug Administration (FDA) clearance for its urine collection and transport system, UriSponge.

UriSponge is designed to address the high volume of urine samples processed annually, which accounts for nearly 70% of all specimens in clinical laboratories.

It provides a user-friendly and cost-effective method for healthcare providers and clinical labs to collect, preserve and transport urine specimens.

The device simplifies the transfer of urine from a sterile container to a tube with the help of a quick dip-and-close method that streamlines workflow and decreases procedural steps.

The system’s screw-cap tube comes with a plastic applicator and sponges with preservatives. These preservatives activate upon contact with urine, maintaining the sample's stability during transport, thereby ensuring ‘reliable’ outcomes and reducing contamination or degradation risks.

Its design eliminates the need for precise fill lines or additional mixing, simplifying the preservation process and reducing the necessity for extra consumables.

The system’s advanced preservatives are key to maintaining specimen integrity, providing an alternative to traditional collection methods that often require strict handling protocols.

UriSponge is also designed to integrate with the company’s laboratory automation systems such as the WASP Walk-Away Specimen Processor, which automates key tasks related to microbiology specimen processing.

This integration with Copan's full laboratory automation solution offers a comprehensive approach to specimen management, from collection to analysis, enhancing laboratory productivity and consistency.

UriSponge will be available through US distribution partners starting early next year. This device is already available across the globe.

Copan Diagnostics CEO Fabrizio Mazzochi said: "Copan is dedicated to advancing laboratory practices through groundbreaking innovation.

"UriSponge provides a reliable and efficient solution that supports laboratory needs while offering healthcare providers a safe, streamlined process."

In January this year, the company received the third FDA clearance for its pre-analytical processor, Colibrí. It features a fully automated specimen preparation platform for MALDI-TOF ID targets and bacterial suspensions for antibiotic susceptibility testing, comprising the Colibrí Vision System and Colibrí Preparation Station.